Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study

Table 2 Patient characteristics at week 52 by low disease activity at week 208 in the adalimumab discontinuation group^a

Abbreviations: ADA Adalimumab, LDA Low disease activity, MTX Methotrexate, TJC Tender joint count, SJC Swollen joint count, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, EGA Evaluator global assessment, PGA Patient global assessment, VAS Visual analogue scale, DAS28 28-joint Disease Activity Score, HAQ Health Assessment Questionnaire, JSN Joint space narrowing, mTSS Modified total Sharp score, MMP-3 Matrix metalloproteinase 3, RF Rheumatoid factor, ACPA Anti-cyclic citrullinated peptide antibody
^a Values are expressed as mean ± SD, unless otherwise indicated
^b Statistical significance assessed by Fisher’s exact test for categorical data and the Wilcoxon rank sum test for continuous data
^c p < 0.01 LDA vs. failed LDA at week 208
^d p < 0.05 LDA vs. failed LDA at week 208

ISSN: 1478-6362